Groupama Asset Managment Acquires 55,539 Shares of Denali Therapeutics Inc. $DNLI

Groupama Asset Managment raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 36.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 207,130 shares of the company’s stock after acquiring an additional 55,539 shares during the period. Groupama Asset Managment’s holdings in Denali Therapeutics were worth $3,977,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Denali Therapeutics in the fourth quarter worth $84,525,000. ADAR1 Capital Management LLC grew its stake in Denali Therapeutics by 3,490.9% during the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock valued at $35,932,000 after acquiring an additional 1,819,339 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Denali Therapeutics by 77.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock valued at $63,329,000 after acquiring an additional 1,672,098 shares during the last quarter. Temasek Holdings Private Ltd increased its holdings in Denali Therapeutics by 30.9% in the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after acquiring an additional 1,657,142 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its stake in Denali Therapeutics by 28.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after purchasing an additional 1,615,565 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $23.02 on Friday. The company has a market cap of $3.65 billion, a price-to-earnings ratio of -7.99 and a beta of 0.96. The firm’s fifty day moving average is $23.12 and its 200 day moving average is $21.07. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 52-week low of $12.58 and a 52-week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same quarter in the prior year, the business posted ($0.78) EPS. Sell-side analysts forecast that Denali Therapeutics Inc. will post -2.73 EPS for the current fiscal year.

Analyst Ratings Changes

DNLI has been the subject of several research reports. Robert W. Baird increased their price objective on shares of Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Deutsche Bank Aktiengesellschaft lifted their target price on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Finally, Morgan Stanley raised their price target on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $35.17.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.